
feb pm et
summari global medic product servic compani provid hospit suppli renal
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
see sale inclus acquisit
clari inject rise
gener competit cyclophosphamid
continu portfolio chang minor
advers impact get facil
puerto rico back normal product level
clari lifesci million clari
inject provid gener inject
medicin anesthesia analges
anti-infect look oper margin
aid
prudent cost cut product portfolio
chang expect cost cut aid margin
basi point year
juli spin-off baxalta
two oper unit hospit
product renal product hospit
product sale billion
see low-single-digit growth next
sever year renal unit sale
billion see low- mid-single-digit
sale growth aid gambro ab
acquisit faster growth acut care
see ep
although view portfolio restructur
posit believ share trade
ep estim peer
near high end rang
near fair valu believ
grow sale compound annual
growth rate expect
oper margin reach
although believ sale goal
achiev cautiou
margin expans goal expect
activ seek supplement organ growth
strateg acquisit achiev
growth forecast follow recent
facil puerto rico advers
impact howev fda grant
regulatori discret temporari special
import certain product
facil ireland australia canada
sale impact million
impact
risk recommend target price
includ failur develop new product
target price base
above-p ep estim
also above-p margin expans
risk assess reflect oper highli
competit busi character rapid
technolog chang new market entrant
addit busi entail regulatori
reimburs risk well liabil risk
malfunct product off-set view
health care product larg immun econom
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview found first produc commerci prepar intraven iv
solut make distribut medic product equip focu
blood circulatori system may divest gener inject busi
spun-off bioscienc unit juli separ trade public compani name baxalta
baxalta produc plasma-bas recombin clot factor hemophilia well
biopharmaceut immun defici cancer disord also offer biosurgeri
product hemostasi tissu seal tissu regener vaccin blood process
storag system use hospit blood bank other also sell mening vaccin
develop cell culture-deriv vaccin influenza smallpox sever acut respiratori syndrom
diseas import bioscienc product advat recombin blood-clot agent
produc without ad human anim protein cell cultur purif final formul
unit make iv solut variou specialti product intraven
solut premix drug pre-fil vial syring iv nutrit product inhal anesthet
product work devic drug-reconstitut system iv infus pump nutrit
compound equip medic manag system provid fluid replenish gener
anesthesia parenter nutrit pain manag antibiot therapi chemotherapi
renal product compris dialysi equip product servic provid kidney
failur patient sell product periton dialysi pd includ solut contain system
autom machin cleans patient blood overnight sleep compani also make
dialyz instrument hemodialysi hd anoth renal care product extran icodextrin
solut facilit increas fluid remov bloodstream dialysi septemb
acquir gambro ab swedish maker dialysi product indic sale
billion billion cash debt
competit landscap although enjoy lead posit key market must still contend
signific competit pressur market competitor bioscienc divis
bayer ag wyeth import manufactur recombin factor viii product
medic deliveri busi compani expect increas price pressur gener
competit inject drug group purchas organ also contend
competit gener form rocephin antibiot propofol anesthet agent renal
segment global region competitor continu expand manufactur capac periton
pipelin research develop activ perform center locat austria belgium
franc japan princip area strateg focu research develop includ
enhanc packag system medic deliveri kidney dialysi drug formul technolog
steril technolog clinic trial studi therapeut use stem cell intraven
immunoglobulin alzheim diseas influenza vaccin therapeut agent
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu view mani product
categori histor recession-resist
expect continu grow albeit
slowli growth procedur rate
slow area normal view
non-elect cardiac rhythm
manag intervent cardiolog
orthoped recent howev equip
maker think certain procedur rate may
stabil start recov
medic devic tax requir
healthcar reform law went effect
januari temporarili
suspend
elect donald trump republican
retain control congress believ
gop abil substanti alter
afford act includ potenti
elimin variou health care sector fee
tax although gop replac
remain uncertain believ
potenti fewer insur patient
neg impact equip sub-industri
fewer insur patient would like lead
fewer procedur anticip
hospit largest buyer
medic equip would also advers
impact could pressur
expect revenu rise constant
currenc mid- upper-singl digit pace
aid new product expans emerg
market case acquisit
still expect extend replac cycl
 hospit area price
demand certain product categori
unfavor foreign exchang continu
hospit becom cautiou regard
base index
five-year market price perform feb
capit budget amid shift
procedur inpati outpati
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
sub-index increas vs rise
 composit index follow
rise health equip
index vs declin
composit index year date
juli health
equip index rose vs rise
 composit index
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
ep sale rose sale grow robust
oversea sale fell hospit product rose renal sale flat
ep vs ahead estim rais sale
guidanc flat growth ep guidanc
expect clari deal close /jeffrey loo cfa
effect februari david scharf resign corpor
vice presid gener counsel connect
resign compani mr scharf enter separ
agreement march provid continu employ
march
inc keep target
peer ep estim set ep
estim believ premium warrant see portfolio
chang lead industri margin spite soft sale ep
vs ahead estim sale rose hospit
product renal sale guid flat sale growth
account gener competit cyclophosphamid product exit
includ pend acquisit clari see ep
et cfra keep hold opinion share baxter
rais target peer
next ep estim view signific margin
expans aid portfolio shift higher margin product ep
vs ahead estim rais
ep estim sale advers
fx rose solid growth driven strong sale fluid
system price iv solut hospit product sale rose
renal sale rose oper margin rose robust
analyst research note compani news
announc mr storm notifi
decis retir board director compani board
audit committe corpor govern committe effect may
day prior compani annual meet connect
mr storm retir mr albert stroucken appoint new
chairman audit committe effect may mr stroucken
serv board audit committe sinc former chairman
presid chief execut offic owens-illinoi inc board
determin mr stroucken audit committe financi expert defin
rule secur exchang commiss
inc rais target above-p
ep estim industri averag
margin expans set ep ep vs
ahead estim sale rose hospit product sale
renal sale puerto rico facil back product
compani expect normal product level come week still
see advers sale impact expect continu
restructur product portfolio acquisit divestitur
inc keep target above-p
forward ep estim faster margin expans
ep vs ahead estim lift ep
estim sale rose hospit product renal
manufactur facil puerto rico remain limit
product fda grant regulatori discret temporari
special import certain product facil ireland
australia canada mexico still expect advers revenu impact
/jeffrey loo cfa
rais target peer
forward ep estim encourag bax
portfolio chang drive growth margin ep vs
ahead estim rais ep estim
estim includ pend acquisit clari
expect close end juli sale rose sale
oversea sale hospit product sale rose renal sale flat
announc appoint cathi smith
board director ms smith also serv baxter audit
committe prior join ms smith serv evp cfo
express script also held evp cfo posit
gamestop other
effect may giusepp accogli formerli corpor vice presid
presid renal chang role
assum role senior vice presid presid global busi
brik eyr formerli corpor vice presid presid hospit
product compani chang role assum role senior vice
presid presid america effect date chang
made connect compani continu portfolio manag
transform effort
inc rais target peer
ep estim see portfolio
chang lead higher margin spite modest sale growth rais
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
